Hum. Reprod. Advance Access originally published online on November 26, 2004
Human Reproduction 2005 20(2):359-367; doi:10.1093/humrep/deh601
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy
Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Vrije Universiteit Medical Centre (VUMC), Amsterdam, The Netherlands
1 To whom correspondence should be addressed at: Department of Obstetrics and Gynaecology, VUMC, P.O.Box 7075, 1007 MB Amsterdam, The Netherlands. Email: cb.lambalk{at}vumc.nl
BACKGROUND: An optimal range of LH concentrations for achieving pregnancy has not been established. The aim of this study was to investigate the effect of various LH levels induced by different GnRH antagonist doses on IVF outcome. METHODS: This was a prospective, single centre study including 144 IVF patients, stimulated with recombinant FSH from cycle day 2, and co-treated with daily GnRH antagonist (antide/Iturelix) (2 mg/2 ml, 1 mg/ml, 0.5 mg/ml, 0.5 mg/0.5 ml or 0.25 mg/ml) from cycle day 7 onwards. Serum samples were taken three times daily. RESULTS: Clinical pregnancies were only observed within a particular range of change in LH levels. The upper and lower thresholds for the mean LH area under the curve (AUC), adjusted for the baseline LH level before the antagonist was started (LH AUC–S6; S6=stimulation day 6) were –2.2 and 12.4 (IU/l) respectively (a negative value=below baseline levels). There were no clinical pregnancies outside these threshold values. Similar results were found for progesterone, the threshold levels of progesterone AUC–S6 were 3.98 and –1.21 ng/ml. Moreover, there were no pregnancies with progesterone levels >0.26 ng/ml/follicle on the day of hCG. CONCLUSIONS: Excessive or insufficient suppression of LH and progesterone levels during GnRH antagonist administration and high progesterone/follicle on hCG day seems to be associated with impaired clinical pregnancy rates.
Key words: GnRH antagonist/IVF/implantation/LH/progesterone
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Kol and R. Homburg Change, change, change: hormonal actions depend on changes in blood levels Hum. Reprod., May 1, 2008; 23(5): 1004 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.A. Huirne, R. Homburg, and C.B. Lambalk Are GnRH antagonists comparable to agonists for use in IVF? Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cedrin-Durnerin, B. Bstandig, I. Parneix, V. Bied-Damon, C. Avril, C. Decanter, and J.N. Hugues Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol Hum. Reprod., January 1, 2007; 22(1): 109 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. E. Messinis Ovarian feedback, mechanism of action and possible clinical implications Hum. Reprod. Update, September 1, 2006; 12(5): 557 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.A. Huirne, J.N. Hugues, C. Pirard, F. Fischl, J.C. Sage, J.L. Pouly, A. Obruca, D.M. Braat, A.C.D. van Loenen, and C.B. Lambalk Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study Hum. Reprod., June 1, 2006; 21(6): 1408 - 1415. [Abstract] [Full Text] [PDF]
|
|